Temocillin - Eumedica Pharmaceuticals
Alternative Names: Negaban; TemopenLatest Information Update: 24 Oct 2021
At a glance
- Originator GlaxoSmithKline
- Class Antibacterials; Penicillins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections
- No development reported Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 21 Apr 2018 Antimicrobial data from a study in Bacterial infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- 16 Apr 2003 No development reported - Clinical-Phase-Unknown for Cystic fibrosis-associated respiratory tract infections in United Kingdom (Parenteral)
- 16 Apr 2003 No development reported - Preclinical for Cystic fibrosis-associated respiratory tract infections in France (unspecified route)